Work

Wcn24-355 Individual Beta Blocker Agents and Mortality in Chronic Hemodialysis Patients: an International Cohort Study

Year: 2024

Type: article

Abstract: Despite a lack of clinical trial data, β-blockers are widely prescribed to dialysis patients. There is considerable heterogeneity among β-blocker medications in terms of key pharmacologic variables such as cardioselectivity and dialyzability. While the majority of existing evidence indicates a survival benefit with β-blocker use in dialysis patients, the optimal β-blocker agent for this population remains uncertain.

Source: Kidney International Reports

DOI: 10.1016/j.ekir.2024.02.645

Authors: Gregory Hundemer, Corey Toye, Manish Sood, Ranjeeta Mallick, Ayub Akbari

Institutions: Ottawa Hospital, Ottawa Hospital Research Institute

Language: English

Topic: Dialysis and Renal Disease Management

Subfield: Nephrology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,800